News

WHO recommends two new lifesaving medicines to treat Ebola |



The introduction after reviewing and analyzing clinical trials for the monoclonal antibodies mAb114 (known as Ansuvilab or Ebanga) and REGN-EB3 (Inmazeb), demonstrated clear benefit for those with test results. tested positive for Ebolaoften fatal.

This includes older adults, pregnant and lactating women, children and infants whose mothers have been confirmed to have Ebola within the first seven days after birth.

Test with fire

Clinical trials were conducted during the Ebola outbreak. WHO said the largest trial has been conducted in the Democratic Republic of Congo, demonstrating that the highest level of scientific rigor can be applied even during Ebola outbreaks in difficult circumstances.

The UN agency also made recommendations regarding therapies that should not be used as treatments, including ZMapp and remdesivir.

The new guidance, published simultaneously in English and French, will assist healthcare providers caring for Ebola patients as well as policymakers involved in preparing for and responding to Ebola. outbreak.

It complements clinical care guidelines outlines the optimal supportive care that Ebola patients should receive – from the tests involved to perform, to pain management, nutrition and co-infections, and other approaches to disease management multiplies the best path to recovery.

‘Higher chance of recovery’

“This therapy guide is an important tool to fight Ebola,” speak Dr. Richard Kojan, co-chair of the expert group selected by WHO to develop the guidelines, and President of ALIMA, the International Alliance for Health Action.

“From now on, people infected with the Ebola virus will have a better chance of recovering if they seek care as soon as possible. As with other communicable diseases, prompt treatment is key, and people should not hesitate to consult a health professional as quickly as possible to ensure they receive the best care possible.” .

Co-chair Dr Robert Fowler from the University of Toronto in Canada noted that Ebola was once considered “an almost certain killer”, but advances in care and treatment over the past decade have created a revolution in the treatment of this disease.

“Providing the best supportive medical care to patients, combined with monoclonal antibody treatment – ​​MAb114 or REGN-EB3 – now leads to recovery for the vast majority of people,” he added. People.

Timely access is important

As access to these treatments remains challenging, especially in poor areas, WHO says they should be available where they are needed most, namely in areas where Ebola outbreaks are occurring. or where there is a high or very high risk of an outbreak.

UN agency ready to support countries, manufacturers and partners to improve access to two drugs.

“We have seen incredible advances in both quality and safety of care,” said Dr. health during the Ebola outbreak.

“Doing the basics well, including early diagnosis, providing optimal supportive care with the evaluation of new treatments in clinical trials, has transformed what can happen. during the Ebola outbreak. This is what has led to the development of a new standard of patient care. However, prompt access to these lifesaving interventions must be a priority”.



Source link

news7f

News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, Sports...at the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button